Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study

Koji Izutsu1 | Kiyoshi Ando2 | Daisuke Ennishi3 | Hirohiko Shibayama4 | Junji Suzumiya5 | Kazuhiro Yamamoto6 | Satoshi Ichikawa7 | Koji Kato8 | Kyoya Kumagai9 | Priti Patel10 | Sakura Izumi11 | Nobuya Hayashi12 | Hisashi Kawasaki11 | Koshir Murayama12 | Hirokazu Nagai13

1 National Cancer Center Hospital, Tokyo, Japan
2 Tokai University Hospital, Isehara, Japan
3 Okayama University Hospital, Okayama, Japan
4 Osaka University Hospital, Osaka, Japan
5 Shimane University Hospital, Izumo, Japan
6 Aichi Cancer Center Hospital, Nagoya, Japan
7 Tohoku University Hospital, Sendai, Japan
8 Kyushu University Hospital, Fukuoka, Japan
9 Chiba Cancer Center, Chiba, Japan
10 Acerta Pharma, South San Francisco, CA, USA
11 AstraZeneca K.K., Tokyo, Japan
12 AstraZeneca K.K., Osaka, Japan
13 National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Correspondence
Koji Izutsu, Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Email: kizutsu@ncc.go.jp

Funding information
AstraZeneca

This multicenter, open-label, phase I study assessed the safety and antitumor activity of acalabrutinib in Japanese patients with relapsed/refractory (r/r) B-cell malignancies. Parts 1 (dose confirmation) and 2 (dose expansion) of this three-part study are reported. Treatment was a single dose of 100 mg acalabrutinib (day 1), followed by a washout period and then twice daily 100 mg acalabrutinib in part 1, or twice daily 100 mg acalabrutinib in part 2. Patients from parts 1 and 2 with r/r chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and r/r mantle cell lymphoma (MCL) were assessed as r/r CLL/SLL and r/r MCL cohorts, respectively. Twenty-five patients received treatment (part 1, n = 6). Median age was 71.0 years. Nine (one patient from part 1 and 13 (two patients from part 1) patients were included in the r/r CLL/SLL and r/r MCL cohorts, respectively. Treatment-related adverse events (AEs) occurred in 88% of patients (grade ≥3, 36%); the most common were headache (28%) and purpura (24%), both grade 1/2. No AEs resulted in treatment discontinuation or death. Median duration of treatment was 31, 20, and 7 months for part 1, r/r CLL/SLL cohort, and r/r MCL cohort, respectively. Overall response rate (ORR) was 89% and 62% for the r/r CLL/SLL and r/r MCL cohorts, respectively. The median progression-free survival (PFS) was not reached for the r/r CLL/SLL cohort and was 7 months for the r/r MCL cohort. Acalabrutinib (100 mg twice daily) was generally safe and well-tolerated in adult Japanese patients with B-cell malignancies.

KEYWORDS
Bruton's tyrosine kinase, chronic lymphocytic leukemia, mantle cell lymphoma, pharmacokinetics, small lymphocytic lymphoma

Abbreviations: AE, adverse event; AUC, area under the curve; BID, twice daily; BTK, Bruton’s tyrosine kinase; CI, confidence interval; CLL, chronic lymphocytic leukemia; Cmax, maximum observed plasma concentration; CR, complete response; CV, coefficient of variation; DLBCL, diffuse large B-cell lymphoma; DLT, dose-limiting toxicity; ECOG, Eastern Cooperative Oncology Group; ELISA, enzyme-linked immunosorbent assay; FL, follicular lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; PRL, partial response with lymphocytosis; PS, performance status; PT, Preferred Term; r/r, relapsed/refractory; SAE, serious adverse event; SLL, small lymphocytic lymphoma; SOC, System Organ Class; ULN, upper limit of normal; WM, Waldenström macroglobulinemia.

Clinical trial registration: ClinicalTrials.gov Identifier: NCT03198650

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1  |  INTRODUCTION

Bruton’s tyrosine kinase (BTK) is a cytoplasmic nonreceptor enzyme of the TEC kinase family and is expressed in cells of hematopoietic origin, including B cells, myeloid cells, mast cells, and platelets. It regulates multiple cellular processes, including proliferation, differentiation, and cell migration. Functional null mutations in BTK cause X-linked agammaglobulinemia, an inherited disease that is characterized by a lack of mature peripheral B cells. BTK activation is implicated in the pathogenesis of several B-cell malignancies, such as B-cell lymphomas and leukemias, as BTK-dependent signals are required for their survival. Together, these findings suggest that BTK inhibition may be an attractive strategy for treating B-cell neoplasms.

Ibrutinib is an oral small-molecule BTK inhibitor that has been approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Additionally, it has shown efficacy in other non-Hodgkin lymphomas (NHLs), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Waldenström macroglobulinemia (WM). While ibrutinib is an effective treatment option, adverse events (AEs) owing to off-target inhibition of other kinases are problematic. As such, there is a need to develop more selective BTK inhibitors with similar efficacy and better safety profiles. Zanubrutinib, another small-molecule BTK inhibitor, has demonstrated efficacy in patients with MCL, CLL/SLL, and WM, and was recently approved to treat MCL by the US Food and Drug Administration (FDA). Zanubrutinib is reported to have greater BTK selectivity than ibrutinib, and in a clinical trial it has demonstrated a trend towards improved safety relative to ibrutinib. However, acalabrutinib has demonstrated higher in vitro kinase selectivity than both ibrutinib and zanubrutinib and therefore may have a more favorable safety profile.

Acalabrutinib is a potent, highly selective orally bioavailable small-molecule BTK inhibitor. It was first approved by the US FDA in 2017 for the treatment of relapsed/refractory (r/r) MCL based on the phase II ACE-LY-004 clinical study results, and for the treatment of CLL and SLL based on the results of the ELEVATE-TN and ASCEND clinical studies. Acalabrutinib was approved in Japan for the treatment of r/r CLL and SLL on January 25, 2021. At the time the present study was initiated, acalabrutinib had not yet been evaluated in the Japanese population and, therefore, we considered that a study to evaluate the safety and efficacy of acalabrutinib in Japanese patients was necessary to facilitate the approval process.

A multicenter, open-label, phase I study was conducted to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of acalabrutinib in adult Japanese patients with r/r B-cell malignancies.

2  |  MATERIALS AND METHODS

2.1  |  Patients

Japanese patients who were ≥20 years of age at enrollment and who had a measurable lymphadenopathy or extranodal lymphoid malignancy (not applicable for patients with CLL or WM), an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤2, adequate hematological and organ function, and a serum amylase ≤1.5 × the upper limit of normal (ULN) or a serum lipase ≤1.5 × ULN were eligible for enrollment in this study. Diagnosis-related inclusion criteria differed for parts 1 and 2 of the study: Patients with a documented diagnosis of nongerminal center DLBCL, MCL, or indolent NHL (FL, CLL/SLL, WM) were eligible for participation in part 1; and patients with a confirmed diagnosis of CLL/SLL or MCL who had relapsed after or been refractory to ≥1 prior therapies and had either active disease (CLL/SLL) or documented failure to achieve at least a partial response (PR) or had documented disease progression after the most recent treatment regimen (MCL) were eligible to participate in part 2.

Main exclusion criteria were known central nervous system involvement of lymphoma/leukemia, the use of any biologically or immunologically based therapies within 4 weeks of the first dose of acalabrutinib, the time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study treatment <5 times the half-life of the previously administered agent(s), prior therapy with B-cell receptor inhibitors including BTK inhibitors or BCL-2 inhibitors, and ongoing immunosuppressive therapy. All enrolled patients provided written informed consent.

2.2  |  Study design and treatments

We conducted a multicenter, open-label, phase I study of acalabrutinib in adult Japanese patients with r/r B-cell malignancies. This study was divided into three parts: part 1 was the dose-confirmation phase, part 2 was the dose-expansion phase, and part 3 was the dose-confirmation phase for combination therapy. The results from parts 1 and 2 are described herein, and a schematic showing the study design for parts 1 and 2 is presented in Figure 1.

For part 1, the primary objective was to assess the safety and tolerability of acalabrutinib in Japanese patients with r/r B-cell malignancies and to define the dose for further clinical evaluation using dose-limiting toxicity (DLT) data. Specifically, 100 mg twice daily (BID) dosing, which had been established overseas as the dose for clinical development, was assessed. The secondary objectives included evaluation of the antitumor activity, pharmacokinetics, and pharmacodynamics of acalabrutinib. For part 2, the primary objective was to determine the safety profile of acalabrutinib in Japanese patients with r/r CLL/SLL or r/r MCL. The secondary objectives included evaluation of the antitumor activity and pharmacodynamics of acalabrutinib. Patients with r/r CLL/
FIGURE 1  Study design. Abbreviations: BID, twice daily; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; r/r, relapsed/refractory; SLL, small lymphocytic lymphoma

SLL or r/r MCL from part 1 and part 2 were analyzed as “r/r CLL/SLL cohort” and “r/r MCL cohort,” respectively, where appropriate.

In part 1, patients received a single oral dose of acalabrutinib on day 1 (100 mg, morning), followed by a washout period of 2 (minimum) to 7 (maximum) days and then a 28-day cycle of BID oral acalabrutinib (100 mg, approximately the same time each day in the morning and evening [12 hours apart]). Acalabrutinib BID could be continued from cycle 2 onwards until the patient experienced disease progression or an unacceptable drug-related toxicity. DLTs were defined as any grade 3 or higher nonhematologic toxicity (except those considered to be a response to supportive therapy, such as alopecia, nausea, vomiting, and diarrhea), grade 4 neutropenia (>7 days in duration), grade 4 thrombocytopenia or the need for a platelet transfusion, grade ≥3 febrile neutropenia, or a toxicity-related dosing delay for >7 consecutive days. In part 2, patients received acalabrutinib at a dose of 100 mg BID orally to further explore tolerability at this dose in two disease cohorts, r/r CLL/SLL (n = 6 to 9) and r/r MCL (n = 10 to 13). In each cohort, patients received treatment for a 28-day cycle (cycle 1), and administration of acalabrutinib continued until the patient experienced disease progression or an unacceptable drug-related toxicity. Furthermore, bacterial, viral, and/or fungal prophylaxis as per institutional standards was allowed for patients who were at risk of such infections.

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation/Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics. The study protocol was approved by the institutional review board at each participating center, and the study was registered at ClinicalTrials.gov (identifier: NCT03198650).

2.4 | Efficacy outcomes

The antitumor activity of acalabrutinib was evaluated by overall response rate (ORR), which was defined as the proportion of patients who achieved a response during the study period as assessed by the investigator; duration of response; and progression-free survival (PFS). Computed tomography scans were to be performed for tumor assessments at the end of cycle 2, cycle 4, and cycle 6, and then again after every three cycles through to cycle 18, at which point they were performed every 6 cycles or more frequently at the investigator’s discretion. Tumor responses were defined using previously published criteria; responses for NHL were assessed using the criteria published in Cheson et al, and responses for WM were assessed using a modified version of the criteria published in Hallek et al (Table S1). and responses for WM were assessed using a modified version of the Third International Workshop on WM Criteria (Table S2).

2.5 | Pharmacokinetic outcomes

In part 1, pharmacokinetic profiles of acalabrutinib and its active metabolite (ACP-5862) were assessed under fasting conditions. Single-dose pharmacokinetics were assessed after a single dose of 100 mg acalabrutinib and multiple-dose pharmacokinetics were assessed on day 8 during BID dosing (100 mg acalabrutinib).

2.6 | Pharmacodynamic outcome

A BTK occupancy enzyme-linked immunosorbent assay (ELISA) was used to evaluate the pharmacodynamic profile of acalabrutinib (Text S1). In part 1, blood samples were collected pre-dose and 4 hours post-dose on day 1 for patients who received a single dose; and pre-dose and 4 hours post-dose on days 1 and 8 of cycle 1, and pre-dose on day 28 of cycles 1 and 2 for patients who received multiple doses. In part 2, blood samples were collected pre-dose and 4 hours post-dose on days 1 and 8 of cycle 1, and pre-dose on day 28 of cycles 1 and 2.

2.3 | Safety outcomes

AEs and events of clinical interest were summarized using System Organ Class (SOC), Preferred Term (PT), and Common Terminology Criteria for Adverse Events grade according to the Medical Dictionary for Regulatory Activities. Hematologic toxicity in r/r CLL patients (excluding r/r SLL patients) was graded according to the International Workshop on CLL. Events of clinical interest were identified based on preclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved BTK inhibitors. Events of clinical interest included cardiac events, cytopenias, hemorrhage, hepatic events, hypertension, infection, interstitial lung disease/pneumonitis, secondary malignancies (excluding skin malignancies), and tumor lysis syndrome.
2.7 | Statistical methods

The number of patients was set based on the study objectives to obtain adequate tolerability, safety, pharmacokinetics data, and pharmacodynamics data while exposing as few patients as possible to the study treatment and procedures. For part 1, it was determined that six patients would be adequate to evaluate the safety and tolerability of acalabrutinib. Six to nine patients (r/r CLL/SLL cohort) and 10 to 13 patients (r/r MCL cohort) would allow for the evaluation of ORR using an exact test with a one-sided significance level of 10% and 80% power (assuming a threshold ORR of 50% and an expected ORR of 85% for r/r CLL/SLL, and a threshold ORR of 40% and an expected ORR of 70% for r/r MCL).

All data were summarized by study part (part 1 or part 2) and cohort, unless stated otherwise. Tumor assessment data from part 1 and part 2 were combined for analysis because the assessments were performed using the same criteria. Frequencies were calculated for categorical variables, summary statistics were calculated for continuous data, and 80%, 90%, and 95% confidence intervals (CIs) were calculated for ORR. The average daily dose of acalabrutinib was calculated as total exposure (mg, total amount of study treatment received)/duration of exposure (last dose date − first dose date) for r/r CLL/SLL in Part 1 + Part 2: n = 9, MCL in Part 1 + Part 2: n = 13.

Patients who received treatment

| Total: n = 25 |
| Part 1: n = 6 |
| CLL/SLL in Part 1 + Part 2: n = 9 |
| MCL in Part 1 + Part 2: n = 13 |

Patients who terminated the study

| Total: n = 9 |
| Part 1: n = 2 |
| CLL/SLL in Part 1 + Part 2: n = 0 |
| MCL in Part 1 + Part 2: n = 8 |

FIGURE 2 Patient disposition. 3 All patients discontinued treatment because their condition worsened. 4 Study termination due to death (n = 2) or progressive disease (PD) (n = 7). 5 Study termination due to PD. 6 Study termination due to death (n = 2) or PD (n = 6). Abbreviations: CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; SLL, small lymphocytic lymphoma

3 | RESULTS

3.1 | Patients

The disposition of patients is shown in Figure 2; in total, 28 patients were enrolled and 25 received treatment at 14 study centers in Japan. The first patient was enrolled on June 27, 2017, and the data cutoff date was March 4, 2020. At the data cutoff, 16 (64%) patients were continuing treatment and nine (36%) patients discontinued the study (two due to death and seven due to disease progression). The two reported deaths were related to progressive/worsening disease.

Twenty-five patients were included in both the safety analysis set and the tumor response analysis set, six were included in the pharmacokinetics analysis set, and 21 were included in the pharmacodynamic analysis set. Four patients were excluded from the pharmacodynamic analysis set because baseline pharmacodynamic data were not available.

Patient characteristics are shown in Table 1. The median patient age was 71.0 years, the majority (19 [76%]) were male, and the mean body mass index was 21.57 kg/m². Most patients had an ECOG PS of 0 (19 [76%]) at baseline. The majority of tumor subtypes were MCL, followed by CLL and SLL.

The disposition of patients is shown in Figure 2; in total, 28 patients were enrolled and 25 received treatment at 14 study centers in Japan. The first patient was enrolled on June 27, 2017, and the data cutoff date was March 4, 2020. At the data cutoff, 16 (64%) patients were continuing treatment and nine (36%) patients discontinued the study (two due to death and seven due to disease progression). The two reported deaths were related to progressive/worsening disease.

Twenty-five patients were included in both the safety analysis set and the tumor response analysis set, six were included in the pharmacokinetics analysis set, and 21 were included in the pharmacodynamic analysis set. Four patients were excluded from the pharmacodynamic analysis set because baseline pharmacodynamic data were not available.

Patient characteristics are shown in Table 1. The median patient age was 71.0 years, the majority (19 [76%]) were male, and the mean body mass index was 21.57 kg/m². Most patients had an ECOG PS of 0 (19 [76%]) at baseline. The majority of tumor subtypes were MCL, followed by CLL and SLL.

3.2 | Safety

The duration of exposure is shown in Table 2. The median treatment duration of acalabrutinib was 31 months for part 1, 20 months for the r/r CLL/SLL cohort (parts 1 and 2), and 7 months for the r/r MCL cohort (parts 1 and 2). The mean percentage of the intended dose of acalabrutinib administered to patients was 89% for part 1, and 93% and 97% for the CLL/SLL and MCL cohorts, respectively, in combined parts 1 and 2. No DLTs were observed.

AEs are listed by number of patients and by number of episodes in Tables S3 and S4, respectively; overall, all 25 patients reported a total of 251 AEs. The most prevalent (n, %) AEs were nasopharyngitis (9, 36%), headache (8, 32%), and rash (7, 28%). AEs considered related to the study treatment were reported by 22 (88%) patients (119 AEs total), the most prevalent (n, %) of which were headache (7, 28%) and purpura (6, 24%).

Grade ≥3 AEs were reported for 14 (56%) patients (35 total events). Nine (36%) patients (16 total events) experienced grade ≥3 AEs that were considered related to treatment. Grade 4 AEs were reported by five (20%) patients and included lymphopenia, neutropenia, thrombocytopenia, hyperuricemia, lymphocyte count decreased, neutrophil count decreased, and white blood cell count decreased.
cell count decreased. Twenty-two (88%) patients reported a total of 95 AEs of clinical interest (Table 3). In addition, six (24%) patients reported a total of six serious adverse events (SAEs) and four (16%) patients reported SAEs related to treatment. No AEs with the outcome of death or AEs/SAEs leading to treatment discontinuation were reported. AEs (total) that occurred in ≥10% of patients and those considered possibly related to treatment that occurred in ≥10% of patients are listed by SOC/PT in Tables S5 and S6, respectively.

One patient experienced a grade 1 AE of interstitial lung disease/pneumonitis that was considered related to the treatment (Table 3). This patient underwent dose interruption and recovered without steroids after being treated with sulfamethoxazole and trimethoprim for interstitial lung disease/pneumonitis. Three patients experienced an SAE of grade 3 pneumonia (Table 3); two of the cases were considered possibly related to the treatment, while the third case was considered not related to the treatment. The pathogen was unknown in all three cases.
### 3.3 | Efficacy

ORR was 89% (8/9 patients; 95% CI: 52, 100) for the r/r CLL/SLL cohort, 100% (9/9 patients; 95% CI: 66, 100) for the r/r CLL/SLL cohort (including PR with lymphocytosis [PRL]), and 62% (8/13 patients; 95% CI: 32, 86) for the r/r MCL cohort (Table 4). The best objective response by tumor subtype is shown in Table 4. For patients with r/r CLL/SLL, two patients achieved complete response (CR) with incomplete bone marrow recovery, and six patients achieved a PR. For patients with r/r MCL, five patients achieved CR, and three patients achieved PR. Two patients with FL achieved PR, and one patient with WM achieved a minor response. For the r/r CLL/SLL cohort, none of the eight patients who responded had progressive disease (PD). For the r/r MCL cohort, three of the eight patients who responded had PD. For both cohorts, the median duration of response could not be estimated. The median PFS for the r/r MCL cohort (combined parts 1 and 2, n = 13; six patients had PD) was 7 months; median PFS was not reached for the r/r CLL/SLL cohort (n = 9; none of the patients had PD). The effect of treatment on tumor response over time for each individual patient in the r/r CLL/SLL and r/r MCL cohorts is illustrated in a swimmer plot (Figure S1A,B).

### 3.4 | Pharmacokinetics

Pharmacokinetic evaluation was performed on patients who participated in part 1 of the study. Individual plasma concentration-time curves for both acalabrutinib and ACP-5862 were variable for the single-dose period (Figure S2A,B) but not for the multiple-dose period (Figure S2C,D). Data from both the single- and multiple-dose periods demonstrated that acalabrutinib was rapidly absorbed and metabolized into ACP-5862.
parameters for acalabrutinib and ACP-5862 for the single- and multiple-dose periods are shown in Table 5. The metabolite to parent ratios were 0.53 and 1.23 to 1.40 for the maximum observed plasma concentration (Cmax) and area under the curve (AUC), respectively, after a single dose, and a respective 0.56 and 1.64 to 1.73 after multiple dosing. The coefficient of variation (CV) of acalabrutinib Cmax was 174%, and the elimination half-life was highly variable after a single dose; interpatient variability was lower after multiple dosing (CVs <30%). Using multiple-dose data, the elimination half-life of acalabrutinib was estimated to be 1.8 h and the accumulation ratios of acalabrutinib and ACP-5862 were 1.69 and 2.72, respectively.

### 3.5 | Pharmacodynamics

Twenty-one patients were evaluated for BTK target occupancy (six patients from part 1, and eight patients from the r/r CLL/SLL cohort and seven patients from the r/r MCL cohort from part 2). The median BTK occupancy 4 hours after a single dose was >99% for patients with CLL, MCL, FL, or WM in part 1 (Figure 3A). Furthermore, the median steady-state BTK occupancy was between 97.5% and 99.5% during the BID dosing phase. In part 2, the median steady-state BTK occupancy ranged from 96.5% to 99.9% and 93.8% to 99.3% in the r/r CLL/SLL and r/r MCL cohorts, respectively (Figure 3B, 3C).

### 4 | DISCUSSION

This is the first clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of the BTK

---

**TABLE 4**  Overall response rate and best objective response rate

| Group                              | Number (%) of patients with a response | 95% CI   |
|------------------------------------|----------------------------------------|----------|
| Part 1 + Part 2                    |                                        |          |
| CLL/SLL cohort (n = 9)             |                                        |          |
| ORR                                | 8 (89)                                 | 52, 100  |
| CR                                 | 0                                      |          |
| CRI                                | 2 (22)                                 |          |
| PR                                 | 6 (67)                                 |          |
| Nonresponse (total)                | 1 (11)                                 |          |
| PRL                                | 1 (11)                                 |          |
| Stable disease                     | 0                                      |          |
| PD                                 | 0                                      |          |
| Clinical PD                        | 0                                      |          |
| Not evaluable                      | 0                                      |          |
| CLL/SLL cohort including PRL (n = 9)|                                        |          |
| ORR                                | 9 (100)                                | 66, 100  |

Note: Abbreviations: CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; CRI, complete response with incomplete bone marrow recovery; MCL, mantle cell lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; PRL, partial response with lymphocytosis; SLL, small lymphocytic lymphoma.

**TABLE 5**  Pharmacokinetic parameters of acalabrutinib and ACP-5862 in the single- and multiple-dosing periods (part 1)

|                              | Acalabrutinib (P) | ACP-5862 (M) | M/P ratio | Acalabrutinib (P) | ACP-5862 (M) | M/P ratio |
|------------------------------|-------------------|--------------|-----------|-------------------|--------------|-----------|
|                              | single dose       | single dose  | single dose| multiple dose     | multiple dose| multiple dose|
| tmax (h), median (min, max)  | 0.735 (0.520, 1.020) | 0.965 (0.900, 4.000) | - | 0.615 (0.470, 1.000) | 0.940 (0.750, 1.080) | - |
| Cmax (ng/mL), Gmean (CV)     | 601.9 (174%)      | 316.5 (260%) | 0.53      | 1120 (30%)       | 629.7 (27%)  | 0.56      |
| AUC0–12 (ng∙h/mL), Gmean (CV)| 890.7 (95%)       | 1092 (124%) | 1.23      | 1208 (25%)       | 1987 (8%)    | 1.64      |
| AUC0–t (ng∙h/mL), Gmean (CV)| 961.7 (79%)       | 1306 (94%)  | 1.36      | 1206 (25%)       | 1985 (8%)    | 1.65      |
| CL/F (L/h), Amean ± SD       | 9.359 ± 12.46     | 10.18 ± 7.986 | 1.40 | 1211 (25%)       | 2099 (7%)    | 1.73      |
| CV                             | 99.54 ± 44.33     | 84.89 ± 19.84 | - | 1.795 ± 0.7404   | 3.216 ± 0.3938 | - |
| V/F (L), Amean ± SD           | 1940 ± 2903       | 219.7 ± 107.1 | - | 2099 (7%)        | 1.73         | - |
| RAC, Amean ± SD               | 1.694 ± 1.275     | 2.722 ± 2.826 | - | 1.163 ± 0.4770   | 1.444 ± 0.8136 | - |
| TC, Amean ± SD                | -                 | -            | -         | 1.694 ± 1.275     | 2.722 ± 2.826 | - |

Note: Abbreviations: Amean, arithmetic mean; AUC, area under the plasma concentration-time curve (from zero to infinity); AUC0–12, area under the plasma concentration-time curve (from zero to 12 h); AUC0–t, area under the plasma concentration-time curve (from zero to the time of the last measurable concentration); CL/F, oral clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Gmean, geometric mean; RAC, extent of accumulation on multiple dosing; TC, time dependency of pharmacokinetics; tmax, time to maximum concentration; V/F, volume of distribution.
FIGURE 3  BTK occupancy for each individual patient from part 1 (dose confirmation) (A) and part 2 (dose expansion) for the CLL/SLL (B) and MCL cohorts (C); data cutoff: May 9, 2019. Abbreviations: BID, twice daily; BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.
inhibitor acalabrutinib in Japanese adults with r/r B-cell malignancies. We report that acalabrutinib was safe and well-tolerated, and that treatment resulted in ORRs for r/r CLL and r/r MCL that were similar to those reported for non-Japanese patient populations with r/r B-cell malignancies who were treated with acalabrutinib. Acalabrutinib was rapidly absorbed, and there was a high level of BTK receptor occupancy.

Regarding safety, headache was commonly observed in the present study (32%), which is in line with the findings reported for the global phase I/II study of acalabrutinib in r/r CLL and the phase II ACE-LY-004 study of acalabrutinib in r/r MCL, in which headache was observed in 43% and 38% of patients, respectively. In all three studies, all reports of headaches were grade 1 or 2. Importantly, there were no AEs leading to treatment discontinuation or death. Overall, the safety findings in the present study were in line with previously reported safety data for acalabrutinib, and no new safety concerns were identified.

When analyzing efficacy, the ORRs for parts 1 and 2 combined were 89%, and 62% for the r/r CLL/SLL and r/r MCL cohorts, respectively. In acalabrutinib-treated patients with CLL, an ORR of 81% was reported for the ASCEND study. The ACE-LY-004 study reported an ORR of 81% for acalabrutinib-treated patients with r/r MCL. Overall, the ORRs for the CLL/SLL and MCL cohorts were in line with previous reports, although the results should be interpreted with caution because of the limited number of patients included in the present study.

Pharmacokinetic evaluation revealed that acalabrutinib was rapidly absorbed and had a mean half-life of 1.8 hours after multiple dosing, and similar results were reported in a phase I/II study of acalabrutinib in patients with CLL. Acalabrutinib was metabolized into ACP-5862, which has approximately 50% potency for BTK inactivation relative to the parent agent acalabrutinib; however, ACP-5862 still has a similar kinase selectivity profile. This resulted in metabolite to parent ratios of 0.53 to 0.56 and 1.23 to 1.64 for for Cmax and AUC, respectively. These data indicate that ACP-5862 may also contribute to efficacy and safety after acalabrutinib administration. Meanwhile, pharmacodynamic evaluation showed that there was a high target coverage with near-complete occupancy, which was similar to the occupancy reported in a previous phase I/II study.

4.1 Limitations

This study had several limitations. First, comparison of efficacy and safety between this study and previous studies of acalabrutinib could not be adequately conducted due to the limited number of patients included in the study. Therefore, current findings should be further investigated in larger studies. Second, efficacy was assessed by study investigators and was not assessed with independent central review. Finally, although all patients enrolled in this study had B-cell malignancies, the inclusion of patients with pathophysiologically distinct diseases adds complexity to the interpretation of these study results.

5 CONCLUSIONS

This phase I study demonstrated that 100 mg BID acalabrutinib was generally safe and well-tolerated in adult Japanese patients with r/r B-cell malignancies. These results were also similar to what has been previously reported in other populations.

ACKNOWLEDGMENTS

The study was funded by AstraZeneca. The authors would like to thank the patients, their families, and all the investigators involved in this study. We thank Sarah Bubeck, PhD, of Edanz Evidence Generation, for providing medical writing support, which was funded by AstraZeneca through EMC KK in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

DISCLOSURE

Koji Izutsu has received research funds from AstraZeneca. Kiyoshi Ando has received research funds from AstraZeneca. Daisuke Ennishi has no conflict of interest to declare. Hirohiko Shibayama has received honoraria from Takeda, Novartis, Celgene, Janssen, Chugai, and Kyowa Kirin; research funds from Janssen, Ono, Celgene, Novartis, Sanofi, AstraZeneca, AbbVie, and Chugai; and scholarships from Astellas, Teijin, Shionogi, Eisai, Sanofi, Taiho, and Nippon Shinyaku. Junji Suzumiya has received honoraria from AstraZeneca, AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eisai, Janssen, and Takeda; and research funds from AstraZeneca, Bayer, Celgene, Chugai, Eisai, Kyowa Kirin, Ono, SimBio, Takeda, and Yakult. Kazuhito Yamamoto has received honoraria from Chugai, Eisai, HUYA/IQVIA, Mundipharma, and Takeda; and research funds from AbbVie, AstraZeneca, Bayer, Celgene, Chugai, Eisai, Incyte/IQVIA, Mundipharma, Nippon Shinyaku, Novartis, Solasla Pharma, SimBio, Yakult, and Zenyaku Kogyo. Satoshi Ichikawa has received research funds from Chugai. Koji Kato has received honoraria from Novartis, Eisai, Janssen, Celgene, Takeda, MSD, Kyowa Kirin, Janssen, Celgene, Ono, Mundipharma, and Sumitomo Dainippon; and research funds from AbbVie, AstraZeneca, Bayer, Celgene, Chugai, Eisai, Incyte/IQVIA, Mundipharma, Nippon Shinyaku, Novartis, Solasla Pharma, SimBio, Yakult, and Zenyaku Kogyo. Kosho Murayama are employed by AstraZeneca. Hirokazu Nagai has received honoraria from Celgene, Takeda, Eisai, Chugai, and Mundipharma; research funds from Bayer, AstraZeneca, Zenyaku Kogyo, Takeda, Mundipharma, SymBio, and Chugai; and scholarships from Chugai.

AUTHORS’ CONTRIBUTION

Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi, Hirohiko Shibayama, Junji Suzumiya, Kazuhito Yamamoto, Satoshi Ichikawa, Koji Kato, Kyoya Kumagai, and Hirokazu Nagai were involved in the collection and assembly of data and in the drafting and final approval of the manuscript. Priti Patel and Hisashi Kawasumi were involved in the study conception, design, and data interpretation, and in
the drafting and final approval of the manuscript. Sakura Iizumi, Nobuya Hayashi, and Kosho Murayama were involved in data interpretation and in the drafting and final approval of the manuscript. All authors agree to be accountable for the accuracy and integrity of this work.

DATA AVAILABILITY STATEMENT
Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy which is described at http://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

ORCID
Koji Izutsu https://orcid.org/0000-0001-9129-8057
Hiroshi Shibayama https://orcid.org/0000-0003-4014-2815
Kazuhiro Yamamoto https://orcid.org/0000-0002-8588-8955
Satoshi Ichikawa https://orcid.org/0000-0003-3163-7197
Koji Kata https://orcid.org/0000-0002-5815-4585
Sakura Iizumi https://orcid.org/0000-0001-6760-152X
Nobuya Hayashi https://orcid.org/0000-0002-5386-5599
Hisashi Kawasumi https://orcid.org/0000-0002-5981-2383
Kosho Murayama https://orcid.org/0000-0003-3301-9966

REFERENCES
1. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.
2. Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58-73.
3. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22:1175-1184.
4. Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58-73.
5. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancies. Front Immunol. 2012;3:119-132.
6. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88-94.
7. de Vos S, Wilson W, Gerecitano J, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of refractory/refractory (R/R) DLBCL: Interim phase 2 results. Haematologica. 2012;51:490.
8. Treon SP. Proteasome inhibitors in Waldenström macroglobulinemia. Blood. 2013;122:3243-3244.
9. Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res. 2020;26:4216-4224.
10. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851-859.
11. Cull G, Simpson D, Opat S, et al. Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial. Blood. 2019;134(Supplement_1):500.
12. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136:2038-2050.
13. U.S. Food & Drug Administration. FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma. Accessed January 14, 2021.
14. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075-13080.
15. Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132:1871.
16. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332.
17. U.S. Food & Drug Administration. FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-acalabrutinib-mantle-cell-lymphoma. Accessed August 28, 2020.
18. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659-667.
19. U.S. Food and Drug Administration. Project Orbi: FDA approves acalabrutinib for CLL and SLL. https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbi-fda-approves-acalabrutinib-cll-and-sll. Accessed July 31, 2020.
20. Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Cib) in patients (Pts) with treatment-naïve chronic lymphocytic leukaemia (CLL). Blood. 2019;134:31.
21. Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus ibrutinib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukaemia. J Clin Oncol. 2020;38(25):2849-2861.
22. Sharman JP, Eyed M, Jurchak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
23. Calquence approved in Japan for CLL. https://news.cision.com/https://fda.gov/drugs/resources-information-approved-drugs/project-orbi-fda-approves-acalabrutinib-cll-and-sll. Accessed January 27, 2021.
24. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-2760.
25. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068.
26. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5455.
27. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström’s Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380-383.
28. Covey T, Gulranjani M, Cheung J, et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study. Blood. 2017;130:1741.
29. Maruyama D, Nagai H, Fukuhara N, et al. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. *Cancer Sci*. 2016;107:1785-1790.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Izutsu K, Ando K, Ennishi D, et al. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. *Cancer Sci*. 2021;112:2405-2415. [https://doi.org/10.1111/cas.14886](https://doi.org/10.1111/cas.14886)